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Beyond nutrition: neuropeptide 
signaling and muscle mass 
maintenance in chronic kidney 
disease
Tiffany K. Roberts1,2 and James L. Bailey1
Muscle wasting is a hallmark of uremic cachexia and has frequently 
been attributed to malnutrition that manifests as anorexia in chronic 
kidney disease. However, recent evidence indicates that proteolytic 
mechanisms are responsible for atrophy. Cheung and colleagues have 
reexamined the links between loss of lean body mass and nutrition. 
They demonstrate that neuropeptide signaling pathways, which 
regulate appetite and energy expenditure, also affect expression of key 
proteins involved in muscle mass maintenance.
Kidney International (2008) 74, 143–145. doi:10.1038/ki.2008.220
1Renal Division, Emory University School of 
Medicine, Atlanta, Georgia, USA; and 2Graduate 
Program in Biochemistry, Cell, and Developmental 
Biology, Emory University Graduate School of Arts 
and Sciences, Atlanta, Georgia, USA
Correspondence: James L. Bailey, Renal Division, 
Emory University School of Medicine, WMB 338, 
1639 Pierce Drive, Atlanta, Georgia 30322, USA.  
E-mail: james.l.bailey@emory.edu
Patients with chronic kidney disease 
(CKD) suffer from cachexia, which is char-
acterized by muscle wasting, loss of pro-
tein stores, a low serum albumin, anorexia, 
and increased energy expenditures. This 
maladaptive response is further exacer-
bated by an inability to effectively utilize 
dietary nutrients. As a consequence, mor-
tality is substantially increased, and treat-
ment strategies to combat this response 
have been only partially successful. A 
study by Cheung et al.1 (this issue) pro-
vides some insight into how these central 
features of cachexia may be intertwined.
Elevated circulating levels of cytokines 
are frequently observed in uremic 
cachexia. Recent evidence indicates 
that cytokines can modify the release 
and/or function of neurotransmitters, 
thereby altering appetite. Leptin, which 
is secreted by adipocytes, is a member 
of the interleukin-6 family of cytokines. 
It communicates with the hypothala-
mus to decrease appetite and results in 
decreased food intake and an increase 
in energy expenditure.2 In fact, admin-
istration of leptin induces anorexia in 
mice.3 The level of leptin is increased 
in the presence of overfeeding, insulin, 
glucocorticoids, and angiotensin II and 
is decreased with fasting, testosterone, 
thyroid, and cold exposure.4
Leptin acts to regulate appetite 
through the melanocortin signaling 
pathway (Figure 1). Cheung and col-
leagues have previously used both gene 
deletion and pharmacologic approaches 
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to demonstrate that uremic cachexia in 
nephrectomized animals can be attenu-
ated by blocking of leptin signaling 
through melanocortin-4 receptor (MC4-
R).5,6 Agouti-related peptide (AgRP) is 
an antagonist of MC4-R. When adminis-
tered to animals with CKD, it resulted in 
increased food intake, normalization of 
basal metabolic rate, and a gain in lean 
body mass.5 This suggests that CKD 
causes a partial defect in the ability of 
endogenous AgRP to block MC4-R, thus 
leading to anorexia.
In earlier studies Cheung et al. found 
that administration of AgRP ameliorated 
uremia. However, the nutritional effect 
of appetite stimulation and additional 
protein intake was not evaluated. In the 
study published in this issue,1 the group 
controlled for differences in caloric and 
protein intake by pair-feeding their ani-
mals. Their findings suggest that treat-
ment with AgRP has beneficial effects 
beyond nutrition in the context of ure-
mic cachexia.
Anorexia is one explanation for 
weight loss in CKD patients. However, 
cachexia is characterized by wasting of 
skeletal muscle, and a poor diet is rarely 
to blame for atrophy.7 Instead, metabolic 
mechanisms regulate dynamic protein 
turnover to maintain muscle mass. A 
key protein in this process is insulin-like 
growth factor-I (IGF-I). IGF-I promotes 
muscle growth by activating the mam-
malian target of rapamycin (mTOR). 
This results in stimulation of both pro-
tein translation in mature myofibers and 
differentiation of muscle stem cells.8 
Additionally, IGF-I preserves muscle 
mass by attenuating the activity of key 
ubiquitin proteasome components via 
inhibition of Forkhead box-O transcrip-
tion factors.8 Conversely, myostatin 
suppresses muscle growth by inhibit-
ing muscle stem-cell proliferation, and 
increased myostatin expression cor-
relates with muscle wasting in many 
conditions.9 Cheung et al. propose 
that myostatin and IGF-I represent two 
opposite but mutually complementary 
systems for regulating muscle mass in 
CKD.1 Expression of IGF-I has been 
shown to be decreased, whereas myosta-
tin expression is increased, in skeletal 
muscle of uremic animals. Now, Cheung 
et al. have demonstrated that treatment 
of rats with AgRP restores both IGF-I 
and myostatin to near normal levels.1
IGF-I is also known to mediate the 
action of growth hormone (GH), and 
both IGF-I and GH resistance are com-
mon in uremia. In children, GH resist-
ance impairs growth, but in adults it is 
thought to contribute to muscle wasting. 
The mechanism that may be responsi-
ble for this is suppression of the Janus 
kinase (JAK)–signal transducer and 
activator of transcription (STAT) 
pathway, which is necessary for IGF-I 
transcription. Cytokines activate the 
JAK–STAT pathway to mediate many 
of their key actions. However, each 
cytokine also stimulates specific sup-
pressor of cytokine signaling (SOCS) 
proteins, which then act as negative 
feedback regulators of JAK–STAT to 
downregulate the signal initiated by the 
cytokine.10 Specifically, upon binding 
to cytokine receptors, JAK-2 under-
goes autophosphorylation on tyrosine 
residues. Subsequently, the STAT3 
transcription factor is recruited to the 
leptin receptor–JAK-2 complex, where 
it undergoes phosphorylation and 
homodimerization. STAT3 then trans-
locates to the nucleus, where it activates 
target genes, including those encoding 
the SOCS proteins. SOCS proteins serve 
as negative regulators of the JAK–STAT 
pathway and possibly some cell recep-
tors. In rats with CKD, SOCS2 and 
SOCS3 expression levels are increased, 
suggesting that these two SOCS pro-
teins may play a key role in the muscle 
wasting associated with uremia.10 It is 
also known that JAK-2 phosphorylates 
tyrosine 985 on the leptin receptor, lead-
ing to SOCS3 binding and inhibition of 
leptin signaling.4
Cheung et al. further explore the role 
of SOCS2 and SOCS3 in their current 
work.1 They confirm that SOCS2 expres-
sion is increased in skeletal muscle of 
uremic rats. AgRP treatment did abate 
the increase but did not return SOCS2 
Figure 1 | Leptin signaling through JAK–STAT and MC4-R Pathway. Leptin binds to its receptor 
(Ob-Rb) to initiate several signaling pathways, including the Janus kinase (JAK)–signal transducer 
and activator of transcription (STAT) and melanocortin pathways. JAK–STAT signaling regulates the 
transcription of numerous proteins, including insulin-like growth factor-I (IGF-I) and suppressor 
of cytokine signaling (SOCS). SOCS proteins, in turn, suppress the JAK–STAT pathway. Leptin also 
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to basal levels. SOCS3 expression was 
unchanged. Consequently, the role of 
SOCS proteins in uremic sarcopenia 
remains elusive. What other pathways 
may be involved? Because JAK-2 phos-
phorylation can lead to activation of the 
mitogen-activated protein kinase and 
other signaling pathways, it is conceivable 
that multiple pathways may be working 
separately or in concert to countermand 
changes in SOCS expression.11 Alterna-
tively, angiotensin II and glucocorticoids, 
which are elevated in uremia, may be 
playing unknown roles. Under conditions 
of inflammation, activated macrophages 
reside in fat tissues and release proinflam-
matory cytokines such as interleukin-6 
and tumor necrosis factor-α, which may 
activate systemic responses.12 What the 
work of Cheung et al.1 underscores is how 
complex intracellular signaling is.
The data presented by Cheung and 
colleagues1 emphasize the importance 
of melanocortin signaling in the patho-
genesis of uremic cachexia. Above and 
beyond its effect on nutrition, inhibition 
of MC4-R signaling may attenuate muscle 
atrophy by normalizing expression of key 
proteins that act to maintain muscle mass. 
These new findings bolster the hypothesis 
that MC4-R antagonists may provide new 
strategies for treatment of multiple facets 
of CKD-associated cachexia.
DISCLOSURE
The authors declared no competing interests.
REFERENCES
1. Cheung WW, Rosengren S, Boyle DL, Mak 
RH. Modulation of melanocortin signaling 
ameliorates uremic cachexia. Kidney Int 2008;  
74: 180–186. 
2. Cheung W, Yu PX, Little BM et al. Role of leptin 
and melanocortin signaling in uremia-associated 
cachexia. J Clin Invest 2005; 115: 1659–1665.
3. Stenvinkel P, Lindholm B, Lönnqvist F et al. 
Increases in serum leptin levels during peritoneal 
dialysis are associated with inflammation and 
a decrease in lean body mass. J Am Soc Nephrol 
2000; 11: 1303–1309.
4. Yang R, Barouch LA. Leptin signaling and obesity: 
cardiovascular consequences. Circ Res 2007; 101: 
545–559.
5. Mak RH, Cheung W. Cachexia in chronic kidney 
disease: role of inflammation and neuropeptide 
signaling. Curr Opin Nephrol Hypertens 2007;  
16: 27–31.
6. Cheung W, Yu PX, Little BM et al. Role of leptin 
and melanocortin signaling in uremia-associated 
cachexia. J Clin Invest  2005; 115: 1659–1665. 
7. Mitch WE. Proteolytic mechanisms, not 
malnutrition, cause loss of muscle mass in kidney 
failure. J Ren Nutr 2006; 16: 208–211.
8. Heszele MFC, Price SR. Insulin-like growth 
factor I: the yin and yang of muscle atrophy. 
Endocrinology 2004; 145: 4803–4805.
9. Joulia-Ekaza D, Cabello G. The myostatin gene: 
physiology and pharmacological relevance. Curr 
Opin Pharmacol 2007; 7: 310–315.
10. Tan JC, Rabkin R. Suppressors of cytokine 
signaling in health and disease. Pediatr Nephrol 
2005; 20: 567–575.
11. Bjørbæk C, Buchholz RM, Davis SM et al. 
Divergent roles of SHP-2 in ERK activation by 
leptin receptors. J Biol Chem 2001; 276:  
4747–4755.
12. Wellen KE, Hotamisligil GS. Obesity-induced 
inflammatory changes in adipose tissue. J Clin 
Invest 2003; 112: 1785–1788.
see original article on page 210
HNF1β and defective 
nephrogenesis: a role for 
interacting partners?
Evelyne Fischer1 and Marco Pontoglio1
The genetic program controlled by transcription factors can be 
modulated by multiple mechanisms. Binding of coactivators or 
corepressors, for example, can modulate the transcription of target 
genes. Dudziak and colleagues identified novel HNF1β-interacting 
proteins that, when overexpressed, affect nephrogenesis. These 
results could improve our understanding of the way HNF1β controls 
kidney development.
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Hepatocyte nuclear factors 1α and 1β 
(HNF1α/TCF1 and HNF1β/TCF2) are 
two closely related homeobox proteins 
whose ancestral gene duplication appeared 
during evolution with the first vertebrates. 
These two proteins contain three func-
tional domains: a dimerization domain at 
the N terminus, a POU-homeobox-DNA-
binding domain, and a C-terminal transac-
tivation domain. HNF1α and HNF1β share 
strong homologies in both the dimerization 
and the DNA-binding domains, account-
ing for the fact that the two proteins are 
able to heterodimerize and to bind to the 
same DNA target sequences.1,2
During development, HNF1β  is 
expressed starting with the first steps 
during organogenesis of liver, lung, pan-
creas, digestive tract, and kidney. In all 
these organs, the expression of HNF1β, 
which persists also in the adult stage, is 
restricted to polarized epithelia. The anal-
ysis of mouse models of HNF1β inacti-
vation has provided new insights into 
its role. HNF1β-deficient mice die very 
early, between 6.5 and 7.5 days postcoi-
tus, because of a defective extraembryonic 
visceral endoderm differentiation,3,4 
preventing the analysis of its functions 
during organogenesis. Liver-specific 
HNF1β inactivation in mice results in 
an abnormal gallbladder and an almost 
complete lack of intrahepatic bile ducts.5 
Overexpression of a dominant-negative 
form of HNF1β or its gene inactivation 
in already formed renal tubules leads to a 
drastic form of polycystic kidney disease 
(PKD).6,7 Gene expression analysis com-
bined with chromatin immunoprecipita-
tion in HNF1β-deficient kidney has shown 
